Alyeska Investment Group L.P. bought a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 45,000 shares of the company's stock, valued at approximately $1,291,000. Alyeska Investment Group L.P. owned about 0.06% of CG Oncology at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of CGON. Foresite Capital Management VI LLC acquired a new stake in CG Oncology during the fourth quarter worth about $63,712,000. Marshall Wace LLP grew its position in CG Oncology by 18,836.0% in the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company's stock valued at $41,818,000 after acquiring an additional 1,450,372 shares in the last quarter. Wellington Management Group LLP boosted its holdings in CG Oncology by 274.4% in the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock valued at $54,792,000 after purchasing an additional 1,400,251 shares during the period. Acorn Capital Advisors LLC acquired a new stake in CG Oncology in the fourth quarter valued at $32,451,000. Finally, Decheng Capital LLC lifted its position in CG Oncology by 16.3% in the fourth quarter. Decheng Capital LLC now owns 6,371,669 shares of the company's stock valued at $182,739,000 after acquiring an additional 892,859 shares during the last quarter. Institutional investors own 26.56% of the company's stock.
Insiders Place Their Bets
In other news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.40% of the company's stock.
CG Oncology Stock Up 6.0%
CG Oncology stock traded up $1.43 during mid-day trading on Monday, hitting $25.17. 234,845 shares of the company were exchanged, compared to its average volume of 1,067,847. The company has a market capitalization of $1.92 billion, a PE ratio of -17.72 and a beta of 1.08. The business has a fifty day moving average of $23.57 and a 200 day moving average of $28.47. CG Oncology, Inc. has a 1-year low of $14.80 and a 1-year high of $40.47.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Research analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.
Wall Street Analysts Forecast Growth
CGON has been the subject of several recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. JPMorgan Chase & Co. started coverage on CG Oncology in a research note on Friday, May 2nd. They issued an "overweight" rating and a $41.00 price target for the company. Royal Bank of Canada upped their target price on shares of CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. Finally, Scotiabank assumed coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 target price for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $57.70.
Get Our Latest Stock Analysis on CG Oncology
About CG Oncology
(
Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Recommended Stories

Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.